ClassID:

2171

A01K2207/10 - CPC Classification

Classification description:

Modified animals Animals modified by protein administration, for non-therapeutic purpose

Recent Application in this class:
#1
20260152731
2026-06-04

CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS

#2
20260060221
2026-03-05

METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION

#3
20260013482
2026-01-15

METHOD FOR CONSTRUCTING AN ANIMAL MODEL OF OPEN-ANGLE GLAUCOMA

#4
20250230207
2025-07-17

COMPOSITION

#5
20250163114
2025-05-22

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

#6
20250017181
2025-01-16

Multiplexed Genome Editing

#7
20250000955
2025-01-02

MAP44 POLYPEPTIDES AND CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF

#8
20240298616
2024-09-12

ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS

#9
20240206438
2024-06-27

SIMPLE AND RAPID CONSTRUCTION OF RAT MODEL OF CONSTIPATION AND USE THEREOF

#10
20230292718
2023-09-21

METHOD FOR CONSTRUCTING MODEL OF VITILIGO AND THE USE OF THE MODEL

#11
20230054101
2023-02-23

Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2

#12
20220361462
2022-11-17

ANIMAL MODEL FOR NEURODEGENERATIVE DISORDERS

#13
20220361461
2022-11-17

METHODS OF PRODUCING GRANULOMAS AND ANIMAL MODELS OF SARCOIDOSIS

#14
20220015338
2022-01-20

Animal models, screening methods, and treatment methods for intraocular diseases or disorders

#15
20210400932
2021-12-30

PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL

#16
20210364500
2021-11-25

Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment

#17
20210139872
2021-05-13

CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS

#18
20210127650
2021-05-06

Method for producing recombinant proteins in insects

#19
20210106697
2021-04-15

Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies

#20
20210100225
2021-04-08

Multiplexed genome editing

#21
20210017543
2021-01-21

Method for preparing non-human primate somatic cell cloned animal

#22
20200229407
2020-07-23

PRODUCTS AND METHODS ASSOCIATED WITH MULTIPLE SCLEROSIS AS A TRANSMISSIBLE PROTEIN MISFOLDING DISORDER

#23
20200170229
2020-06-04

Multiplexed genome editing

#24
20200131236
2020-04-30

Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity by UPF1

#25
20200093916
2020-03-26

Recombinant HIV compositions and uses thereof in animal models

#26
20200080111
2020-03-12

Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof

#27
20200000070
2020-01-02

MOUSE MODEL OF RETINAL DEGENERATION

#28
20190364858
2019-12-05

Development of YY male fish broodstocks in a single generation

#29
20190350177
2019-11-21

Multiplexed genome editing

#30
20190289835
2019-09-26

Mouse Models Having a Knockin Scavenger Receptor Class B Type I

#31
20190069527
2019-03-07

MOUSE MODEL OF RETINAL DEGENERATION

#32
20190014758
2019-01-17

HUMANIZED MOUSE MODEL

#33
20180288983
2018-10-11

Multiplexed genome editing

#34
20180273628
2018-09-27

GENERATION OF HUMAN MACROPHAGES IN IMMUNODEFICIENT NON-HUMAN HOSTS

#35
20180160660
2018-06-14

MOUSE MODEL OF RETINAL DEGENERATION

#36
20170306307
2017-10-26

CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS

#37
20170266322
2017-09-21

ANIMAL MODEL OF NEURONAL INJURY

#38
20170202878
2017-07-20

Method for Preventing or Treating a Protein Aggregation Disease

#39
20170105394
2017-04-20

MOUSE MODEL OF RETINAL DEGENERATION

#40
20170002064
2017-01-05

VH4 ANTIBODIES AGAINST GRAY MATTER NEURON AND ASTROCYTE

#41
20160339121
2016-11-24

Animal models for evaluating pharmaceutical compounds

#42
20160242397
2016-08-25

MOUSE MODEL OF RETINAL DEGENERATION

#43
20160069868
2016-03-10

Methods of identifying compounds for the treatment of fibrosis by using S1PR5

#44
20150297754
2015-10-22

Animal model of neuronal injury

#45
20150259391
2015-09-17

Methods of reducing TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis by a UPF1 polypeptide or polynucleotide

#46
20150024007
2015-01-22

Long term disease modification using immunostimulatory oligonucleotides

#47
20120136044
2012-05-31

Compositions And Methods Of Inhibiting NADPH Oxidase Expression

#48
20110243981
2011-10-06

Conjugates comprising mannan and myelin oligodentrocyte glycoprotein (MOG)

#49
20110239318
2011-09-29

METHODS FOR PRODUCING FISH WITH HIGH LIPID CONTENT

#50
20110118341
2011-05-19

Long term disease modification using immunostimulatory oligonucleotides

#51
20110034540
2011-02-10

CYP46A1 gene for the treatment of alzheimer's disease

#52
20100275278
2010-10-28

ANIMAL MODEL FOR HIV INDUCED DISEASE

#53
20100275277
2010-10-28

Infected nail of animal infected with fungus

#54
20100273854
2010-10-28

COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION

#55
20100260726
2010-10-14

Methods for producing a non human model for aortic aneurysm

#56
20100086489
2010-04-08

Osteopenia animal model

#57
20100077498
2010-03-25

COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE

#58
20090317366
2009-12-24

Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF

#59
20090155243
2009-06-18

Mouse model of retinal degeneration

#60
20090093427
2009-04-09

Articular cartilage gene therapy with recombinant vector encoding BMP-7

#61
20080247994
2008-10-09

DNA vaccine

#62
20080214440
2008-09-04

VASOACTIVE INTESTINAL POLYPEPTIDE COMPOSITIONS

#63
20080172751
2008-07-17

Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2

#64
20080171705
2008-07-17

METHODS OF INDUCING AND TREATING VASCULAR DISEASE

#65
20070186289
2007-08-09

Animal model for HIV induced disease

#66
20070079390
2007-04-05

Animal model for schizophrenia